Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025.
ESCMID Global 2025 - the Congress of the European Society of Clinical Microbiology and Infectious Diseases - ran from April 11-15 in Vienna, and was attended by an audience of leading experts in infectious diseases and clinical microbiology.
Amprologix presented results from a robust MRSA skin infection model that have demonstrated a single dose of epidermicin NI01 is as effective as the current standard of care. Further pre-clinical development is now planned to explore whether the compound can be incorporated within gel-type therapies to be applied directly to the skin.
